Amy Boland’s Last Option Was a Bispecific Antibody Drug for Lymphoma. It Worked.
source: pixabay.com

Amy Boland’s Last Option Was a Bispecific Antibody Drug for Lymphoma. It Worked.

  In a recent article that appeared in Science Magazine, Amy Boland described her twelve-year quest to find a cure for the cancer that invaded her lymph system. At first,…

Continue Reading Amy Boland’s Last Option Was a Bispecific Antibody Drug for Lymphoma. It Worked.
Amy Boland’s Last Option Was a Bispecific Antibody Drug for Lymphoma. It Worked.
source: pixabay.com

Amy Boland’s Last Option Was a Bispecific Antibody Drug for Lymphoma. It Worked.

  In a recent article that appeared in Science Magazine, Amy Boland described her twelve-year quest to find a cure for the cancer that invaded her lymph system. At first,…

Continue Reading Amy Boland’s Last Option Was a Bispecific Antibody Drug for Lymphoma. It Worked.
Coronavirus/COVID-19: What Cancer Patients, Caregivers, and Survivors Need to Know
source: pixabay.com

Coronavirus/COVID-19: What Cancer Patients, Caregivers, and Survivors Need to Know

According to a story from LocalHealthGuide, COVID-19 has continued to spread through the US and the lackluster government response suggests that it isn't going to be contained any time soon.…

Continue Reading Coronavirus/COVID-19: What Cancer Patients, Caregivers, and Survivors Need to Know
Experimental CAR NK-Cell Therapy Produces Results in Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphona
source: pixabay.com

Experimental CAR NK-Cell Therapy Produces Results in Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphona

According to a story from Targeted Oncology, a recent phase 1/2a clinical trial of an experimental treatment called TAK-007 produced a clinical response in the majority of patients in the…

Continue Reading Experimental CAR NK-Cell Therapy Produces Results in Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphona
Positive Data Released from Early Adult T-Cell Leukemia/Lymphoma Trial
source: pixabay.com

Positive Data Released from Early Adult T-Cell Leukemia/Lymphoma Trial

According to a story from Financial Buzz, the biopharmaceutical company miRagen Therapeutics has recently announced the release of new data from its phase I clinical study. This trial is testing…

Continue Reading Positive Data Released from Early Adult T-Cell Leukemia/Lymphoma Trial

Pediatric Cancer and the 70th Anniversary of the Leukemia & Lymphoma Society

  When the Leukemia & Lymphoma Society (LLS) was founded in 1949 by a family in memory of their sixteen-year-old son, cancer was considered a hopeless condition. As noted recently…

Continue Reading Pediatric Cancer and the 70th Anniversary of the Leukemia & Lymphoma Society

FDA Approves a Combination of Drugs for Diffuse Large B-cell Lymphoma

  Diffuse large B-cell lymphoma  (DLBCL) is a common type of non-Hodgkins lymphoma. World Pharma News recently reported that the FDA approved the first chemoimmunotherapy, Polivy, for DLBCL in combination with…

Continue Reading FDA Approves a Combination of Drugs for Diffuse Large B-cell Lymphoma

Despite New Rules, Extreme Costs Make Hospitals Balk at Offering the Latest and Greatest Therapies

According to a story from statnews.com, new, groundbreaking forms of treatment, such as gene therapy and CAR-T cell therapy, are giving patients with rare genetic disorders and advanced cancers more…

Continue Reading Despite New Rules, Extreme Costs Make Hospitals Balk at Offering the Latest and Greatest Therapies

Accelerated Approval Granted to a Novel Drug Combination That Treats Patients with a Common Type of Non-Hodgkin Lymphoma

  Each year over eighteen thousand people in the United States are diagnosed with diffuse large B-cell lymphoma (DLBCL) a common type of non-Hodgkin lymphoma. A recent FDA news release…

Continue Reading Accelerated Approval Granted to a Novel Drug Combination That Treats Patients with a Common Type of Non-Hodgkin Lymphoma
Utility of Allogeneic Stem Cell Transplant in Non-Hodgkin Lymphoma Unclear, Report Says
sasint / Pixabay

Utility of Allogeneic Stem Cell Transplant in Non-Hodgkin Lymphoma Unclear, Report Says

According to a story from Science Daily, a review of studies focused on allogeneic stem cell transplants as a treatment for non-Hodgkin lymphoma found that it wasn't possible to conclude…

Continue Reading Utility of Allogeneic Stem Cell Transplant in Non-Hodgkin Lymphoma Unclear, Report Says

A Look at Progress in Healthcare and a Glimpse into the Future

  The Asco Post recently interviewed Dr. Jean Pierre Bizzari, the Executive Vice President of Celgene, a multinational bioparmaceutical company. The interview covered various aspects of research and development (R&D)…

Continue Reading A Look at Progress in Healthcare and a Glimpse into the Future
Possible Treatment for Marginal Zone Lymphoma Earns Orphan Drug Designation
GDJ / Pixabay

Possible Treatment for Marginal Zone Lymphoma Earns Orphan Drug Designation

According to a story from globenewswire.com, the biopharmaceutical company TG Therapeutics, Inc. recently made an announcement declaring that the US Food and Drug Administration (FDA) had awarded the company Orphan…

Continue Reading Possible Treatment for Marginal Zone Lymphoma Earns Orphan Drug Designation

Preliminary Data from Phase 1 Trial for Multiple Myeloma Indicates Complete Response in a Patient

Phase 1 Trial A Phase 1 trial by Gamida Cell is examining a new potential treatment option for patients with multiple myeloma and relapsed/refractory non-Hodgkin's lymphoma who have not responded…

Continue Reading Preliminary Data from Phase 1 Trial for Multiple Myeloma Indicates Complete Response in a Patient
67 Year Old Non-Hodgkin’s Lymphoma Patient Given Second Chance at Life After Experimental Cell Therapy
source: pixabay.com

67 Year Old Non-Hodgkin’s Lymphoma Patient Given Second Chance at Life After Experimental Cell Therapy

  A grandmother of four in Maryland has recently become the first cancer patient to complete the experimental CAR-T cell procedure at Georgetown University Hospital. Daisy Diggs 67, who was…

Continue Reading 67 Year Old Non-Hodgkin’s Lymphoma Patient Given Second Chance at Life After Experimental Cell Therapy

A Recap on 2018: Record Number of Drugs Approved by the FDA for Rare Diseases

Each year the Food and Drug Administration approves dozens of new therapies to fulfill unmet needs for various patient populations. It's just been published that in 2018 they approved a…

Continue Reading A Recap on 2018: Record Number of Drugs Approved by the FDA for Rare Diseases
Rare Blood Cancer Trial Data to be Presented in Upcoming Conference
allinonemovie / Pixabay

Rare Blood Cancer Trial Data to be Presented in Upcoming Conference

According to a story from investors.amgen.com, the drug developer Amgen recently announced its intent to present all new clinical trial data which will feature its latest work in testing a…

Continue Reading Rare Blood Cancer Trial Data to be Presented in Upcoming Conference
Close Menu